What serum sodium target should be maintained in a patient with an acute intracerebral hemorrhage?

Sodium Target for Intracerebral Hemorrhage

In patients with acute intracerebral hemorrhage (ICH), maintain serum sodium levels between 135-145 mmol/L, avoiding both hyponatremia (which worsens cerebral edema) and hypernatremia at discharge (which increases post-discharge mortality).

Target Range and Rationale

The optimal sodium management in ICH differs fundamentally from traumatic brain injury, where prolonged hypernatremia is not recommended 1. For ICH specifically:

• Lower threshold: ≥135 mmol/L - Hyponatremia at presentation is independently associated with increased 90-day mortality (adjusted OR 1.81,95% CI 1.28-2.57) in ICH patients 2. This mortality risk appears independent of hematoma expansion or perihematomal edema growth.

• Upper threshold: ≤145 mmol/L - Hypernatremia at hospital discharge (Na >145 mmol/L) predicts 30-day post-discharge mortality with an adjusted OR of 1.87 (95% CI 1.40-2.48) 3. This represents a robust predictor even after adjusting for disease severity.

Management Algorithm

For Hyponatremia (Na <135 mmol/L):

Determine the underlying cause first:

1. If hypovolemic (cerebral salt wasting - CSW):

   • Treat with IV fluid replacement (normal saline) and sodium supplementation 4
   • Add fludrocortisone 0.1-0.2 mg daily for 7 days 4
   • Target correction rate: 6 mmol/L over 6 hours if severely symptomatic (seizures, altered mental status), then slow to maximum 8 mmol/L total in 24 hours 4
   • Continue treatment until Na reaches 131 mmol/L 4
   • Monitor sodium every 2 hours in ICU if severe symptoms 4

2. If euvolemic (SIADH):

   • Fluid restriction to 1L/24 hours for mild symptoms 4
   • Use 3% hypertonic saline only if severely symptomatic 4
   • Critical caveat: Do NOT use fluid restriction in ICH patients at risk of cerebral ischemia from mass effect 4

For Large ICH (>30 cc) or Symptomatic Perihematomal Edema:

Consider maintaining serum sodium at 140-150 mmol/L for 7-10 days to minimize edema expansion and mass effect 5. This represents a mild, controlled hypernatremia strategy distinct from the aggressive hypernatremia discouraged in traumatic brain injury.

• Use hypertonic saline (3% continuous infusion via central line or 23.4% bolus) 5, 6
• Reserve mannitol and HTS for emergent situations: worsening cerebral edema, elevated ICP, or impending herniation 5
• Monitor serum sodium and chloride closely to avoid excessive hypernatremia 6

Critical Pitfalls to Avoid

1. Overcorrection: Never exceed 8-10 mmol/L correction in 24 hours to prevent osmotic demyelination syndrome 4. Chronic hyponatremia should not be rapidly corrected 4.

2. Fluid restriction in ICH: Unlike SIADH in other contexts, fluid restriction in ICH patients can precipitate cerebral infarction, particularly with mass effect from the hematoma 4. A retrospective analysis showed 21 of 26 fluid-restricted ICH patients developed cerebral infarction 4.

3. Ignoring discharge sodium: Patients leaving the hospital with Na >145 mmol/L have nearly double the post-discharge mortality risk 3. Normalize sodium before discharge when possible.

4. Prolonged hypernatremia for ICP control: The evidence against sustained hypernatremia in traumatic brain injury 1 suggests caution with this approach in ICH, though short-term use (7-10 days) for large hemorrhages with significant edema may be reasonable 5.

Monitoring Protocol

• Severe symptoms or Na <120 mmol/L: Check sodium every 2 hours in ICU 4
• Mild symptoms: Check sodium every 4 hours 4
• Stable patients: Daily sodium monitoring 4
• Monitor daily weights and strict intake/output 4

Special Considerations

The relationship between sodium and ICH outcomes is U-shaped: both hyponatremia and hypernatremia worsen outcomes 3, 2. This differs from the linear relationship sometimes seen in other neurological conditions. The safest zone appears to be 139-141 mmol/L based on mortality data 3, though the broader range of 135-145 mmol/L provides practical clinical targets.

For small ICH without significant mass effect, routine use of hypertonic saline or mannitol is not indicated 5. Reserve osmotherapy for patients with clinical deterioration or radiographic evidence of dangerous mass effect.